Journal article
Proposed mechanisms of action for prostate cancer vaccines
Nature reviews. Urology, Vol.10(3), pp.149-160
03/2013
DOI: 10.1038/nrurol.2013.8
PMCID: PMC4358823
PMID: 23399727
Abstract
Prostate cancer is responsible for the deaths of more than 33,000 American men every year. Once this disease has become metastatic, there is no curative treatment. Alternative therapies to chemotherapy and radical prostatectomy are being increasingly explored. Prostate cancer vaccines--which trigger a tumour-specific cytotoxic-T-lymphocyte-mediated immune attack by the patient's immune system--have been investigated in clinical trials with modest, yet encouraging, results. When developing and administering prostate cancer vaccines, it is critical to consider how vital parameters, such as the stage of disease progression and the nature of adjuvant therapies, could influence treatment outcome. Of particular interest are current and future strategies for diminishing the activity of regulatory T lymphocytes.
Details
- Title: Subtitle
- Proposed mechanisms of action for prostate cancer vaccines
- Creators
- Sean M Geary - Division of Pharmaceutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USACaitlin D LemkeDavid M LubaroffAliasger K Salem
- Resource Type
- Journal article
- Publication Details
- Nature reviews. Urology, Vol.10(3), pp.149-160
- DOI
- 10.1038/nrurol.2013.8
- PMID
- 23399727
- PMCID
- PMC4358823
- NLM abbreviation
- Nat Rev Urol
- ISSN
- 1759-4820
- eISSN
- 1759-4820
- Publisher
- England
- Grant note
- P50CA09727411 / NCI NIH HHS 1R21CA13345-01 / NCI NIH HHS P30 CA086862 / NCI NIH HHS R21 CA133456 / NCI NIH HHS
- Language
- English
- Date published
- 03/2013
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Pharmaceutical Sciences and Experimental Therapeutics; Craniofacial Anomalies Research Center; Urology; Dental Research; Chemical and Biochemical Engineering; Holden Comprehensive Cancer Center
- Record Identifier
- 9983986464702771
Metrics
14 Record Views